|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 July 2021 |
|
Main ID: |
NCT04945811 |
|
Date of registration:
|
29/06/2021 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Role of Interleukin-6 and Procalcitonin as Novel Inflammatory Biomarkers in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta
|
|
Scientific title:
|
Role of Interleukin-6 and Procalcitonin in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta |
|
Date of first enrolment:
|
April 1, 2020 |
|
Target sample size:
|
100 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT04945811 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Pakistan
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- positive PCR of COVID 19
Exclusion Criteria:
- NEGATIVE PCR of COVID 19
Age minimum:
38 Years
Age maximum:
71 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Covid19 Positive Patients
|
|
Intervention(s)
|
|
Diagnostic Test: Interlukein 6 and procalcitonin serum levels
|
|
Primary Outcome(s)
|
|
Levels of inflammatory biomarkers is raised in accordance with severity of COVID 19
[Time Frame: 2 days]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|